Literature DB >> 29574689

Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis.

Francisco Espejo-Porras1,2,3, Laura García-Toscano1,2,3, Carmen Rodríguez-Cueto1,2,3, Irene Santos-García1,2,3, Eva de Lago1,2,3, Javier Fernandez-Ruiz1,2,3.   

Abstract

BACKGROUND AND
PURPOSE: Cannabinoid CB2 receptors are up-regulated in reactive microglia in the spinal cord of TDP-43 (A315T) transgenic mice, an experimental model of amyotrophic lateral sclerosis. To determine whether this up-regulation can be exploited pharmacologically, we investigated the effects of different treatments that affect CB2 receptor function. EXPERIMENTAL APPROACH: We treated TDP-43 (A315T) transgenic mice with the non-selective agonist WIN55,212-2, alone or combined with selective CB1 or CB2 antagonists, as well as with the selective CB2 agonist HU-308, and evaluated their effects on the pathological phenotype. KEY
RESULTS: WIN55,212-2 had modest beneficial effects in the rotarod test, Nissl staining of motor neurons, and GFAP and Iba-1 immunostainings in the spinal cord, which were mediated in part by CB2 receptor activation. HU-308 significantly improved the rotarod performance of the transgenic mice, with complete preservation of Nissl-stained motor neurons in the ventral horn. Reactive astrogliosis labelled with GFAP was also attenuated by HU-308 in the dorsal and ventral horns, in which CB2 receptors colocalize with this astroglial marker. Furthermore, HU-308 reduced the elevated Iba-1 immunostaining in the ventral horn of TDP-43 transgenic mice, but did not affect this immunoreactivity in white matter, in which CB2 receptors also colocalize with this microglial marker. CONCLUSIONS AND IMPLICATIONS: Our study shows an important role for glial CB2 receptors in limiting the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice. Such benefits appear to derive from the activation of CB2 receptors concentrated in astrocytes and reactive microglia located in spinal dorsal and ventral horns. LINKED ARTICLES: This article is part of a themed section on 8th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29574689      PMCID: PMC6487601          DOI: 10.1111/bph.14216

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

1.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  The epidemiology of ALS: a conspiracy of genes, environment and time.

Authors:  Ammar Al-Chalabi; Orla Hardiman
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 3.  Spinal Cord Anatomy and Clinical Syndromes.

Authors:  Eric Diaz; Humberto Morales
Journal:  Semin Ultrasound CT MR       Date:  2016-05-06       Impact factor: 1.875

4.  Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.

Authors:  Eva de Lago; Miguel Moreno-Martet; Ana Cabranes; José A Ramos; Javier Fernández-Ruiz
Journal:  Neuropharmacology       Date:  2012-02-08       Impact factor: 5.250

5.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

6.  TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.

Authors:  Iga Wegorzewska; Shaughn Bell; Nigel J Cairns; Timothy M Miller; Robert H Baloh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-15       Impact factor: 11.205

7.  Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets.

Authors:  Francisco J Alvarez; Hector Lafuente; M Carmen Rey-Santano; Victoria E Mielgo; Elena Gastiasoro; Miguel Rueda; Roger G Pertwee; Ana I Castillo; Julián Romero; José Martínez-Orgado
Journal:  Pediatr Res       Date:  2008-12       Impact factor: 3.756

Review 8.  Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.

Authors:  Javier Fernández-Ruiz; María A Moro; José Martínez-Orgado
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 9.  Modelling amyotrophic lateral sclerosis: progress and possibilities.

Authors:  Philip Van Damme; Wim Robberecht; Ludo Van Den Bosch
Journal:  Dis Model Mech       Date:  2017-05-01       Impact factor: 5.758

10.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors.

Authors:  Stephen Ph Alexander; John A Cidlowski; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

View more
  21 in total

1.  Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis.

Authors:  Francisco Espejo-Porras; Laura García-Toscano; Carmen Rodríguez-Cueto; Irene Santos-García; Eva de Lago; Javier Fernandez-Ruiz
Journal:  Br J Pharmacol       Date:  2018-05-06       Impact factor: 8.739

Review 2.  Interaction of Cannabis Use and Aging: From Molecule to Mind.

Authors:  Hye Bin Yoo; Jennifer DiMuzio; Francesca M Filbey
Journal:  J Dual Diagn       Date:  2019-09-30

3.  Cannabinoids and their actions: An update.

Authors:  Stephen P H Alexander; Francisco Molina-Holgado
Journal:  Br J Pharmacol       Date:  2019-05       Impact factor: 8.739

4.  Activating cannabinoid receptor 2 preserves axonal health through GSK-3β/NRF2 axis in adrenoleukodystrophy.

Authors:  Janani Parameswaran; Leire Goicoechea; Laura Planas-Serra; Antoni Pastor; Montserrat Ruiz; Noel Y Calingasan; Cristina Guilera; Ester Aso; Jordi Boada; Reinald Pamplona; Manuel Portero-Otín; Rafael de la Torre; Isidre Ferrer; Carlos Casasnovas; Aurora Pujol; Stéphane Fourcade
Journal:  Acta Neuropathol       Date:  2022-07-01       Impact factor: 15.887

5.  The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders.

Authors:  Qing Xin; Fei Xu; Devin H Taylor; Jing-Fu Zhao; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2020-10-06       Impact factor: 6.150

6.  Cannabinoid CB2 Receptor Modulation by the Transcription Factor NRF2 is Specific in Microglial Cells.

Authors:  M Galán-Ganga; R Del Río; N Jiménez-Moreno; M Díaz-Guerra; I Lastres-Becker
Journal:  Cell Mol Neurobiol       Date:  2019-08-05       Impact factor: 5.046

7.  Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration.

Authors:  M Galán-Ganga; C Rodríguez-Cueto; J Merchán-Rubira; F Hernández; J Ávila; M Posada-Ayala; J L Lanciego; E Luengo; M G Lopez; A Rábano; J Fernández-Ruiz; I Lastres-Becker
Journal:  Acta Neuropathol Commun       Date:  2021-05-17       Impact factor: 7.801

8.  Activating Cannabinoid Receptor 2 Protects Against Diabetic Cardiomyopathy Through Autophagy Induction.

Authors:  Aiping Wu; Pengfei Hu; Jian Lin; Wan Xia; Rui Zhang
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

9.  Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment.

Authors:  Loreto Martínez-González; Carmen Rodríguez-Cueto; Diego Cabezudo; Fernando Bartolomé; Pol Andrés-Benito; Isidro Ferrer; Carmen Gil; Ángeles Martín-Requero; Javier Fernández-Ruiz; Ana Martínez; Eva de Lago
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

10.  Brainstem Involvement in Amyotrophic Lateral Sclerosis: A Combined Structural and Diffusion Tensor MRI Analysis.

Authors:  Haining Li; Qiuli Zhang; Qianqian Duan; Jiaoting Jin; Fangfang Hu; Jingxia Dang; Ming Zhang
Journal:  Front Neurosci       Date:  2021-06-02       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.